When to start tacrolimus ointment for vernal keratoconjunctivitis? A proposed treatment protocol.
Lubrication
Steroids
Tacrolimus
Vernal keratoconjunctivitis
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
06
07
2021
accepted:
18
12
2021
pubmed:
5
1
2022
medline:
3
6
2022
entrez:
4
1
2022
Statut:
ppublish
Résumé
The aim of this study was to compare treatment regimens of tacrolimus and of topical steroids for VKC and suggest a treatment protocol according to our clinical experience. This retrospective, nonrandomized case series enrolled 85 patients with VKC. Patients were classified clinically according to severity (mild, moderate, severe) and were treated according to a suggested protocol. Analysis was made according to treatment received: tacrolimus ointment as first line treatment (tacrolimus 1st line), tacrolimus ointment after topical steroid drops treatment (tacrolimus 2nd line) and topical steroid drops or artificial tears alone (topical steroid and tears group). Significant improvements in clinical signs and symptoms were achieved under tacrolimus treatment 14 months in the moderate group and 5 months in the severe group. The longest duration of treatment was for tacrolimus 2nd line group (p = 0.031) and the mean number of visits in the clinic was the highest. The mean number of topical treatments per day was higher in the topical steroid and tears group (2.6 times) than in the two tacrolimus groups (1.3 times for both). The mean time needed to achieve disease remission or relief did not differ between the tacrolimus 1st line and 2nd line groups. Tacrolimus treatment is effective and safe for VKC. Tacrolimus as 1st line treatment may be preferred for severe cases, for faster disease remission compared to tacrolimus as 2nd line treatment; and with fewer topical treatments per day compared to topical steroids.
Identifiants
pubmed: 34981294
doi: 10.1007/s10792-021-02174-5
pii: 10.1007/s10792-021-02174-5
doi:
Substances chimiques
Immunosuppressive Agents
0
Ointments
0
Steroids
0
Tacrolimus
WM0HAQ4WNM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1771-1780Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Addis H, Jeng BH (2018) Vernal keratoconjunctivitis. Clin Ophthalmol 12:119–123
doi: 10.2147/OPTH.S129552
Saboo U, Sangwan V, Jain M, Reddy J (2013) Demographic and clinical profile of vernal keratoconjunctivitis at a tertiary eye care center in India. Indian J Ophthalmol 61(9):486
doi: 10.4103/0301-4738.119431
Nebbioso M, Iannaccone A, Duse M, Aventaggiato M, Bruscolini A, Zicari AM (2018) Vascular endothelial growth factor (VEGF) serological and lacrimal signaling in patients affected by vernal keratoconjunctivitis (VKC). J Ophthalmol 2018:3850172
pubmed: 30305958
pmcid: 6165591
Kim SE, Quartilho A, Larkin F, Hingorani M, Tuft S, Dahlmann-Noor A (2019) Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD013298
doi: 10.1002/14651858.CD013298
pubmed: 31476271
pmcid: 6872160
Bonini S, Coassin M, Aronni S, Lambiase A (2004) Vernal keratoconjunctivitis. Eye 18(4):345–351
doi: 10.1038/sj.eye.6700675
Leonardi A (2013) Management of vernal keratoconjunctivitis. Ophthalmol Ther 2(2):73–88
doi: 10.1007/s40123-013-0019-y
Nebbioso M, Alisi L, Giovannetti F, Armentano M, Lambiase A (2019) Eye drop emulsion containing 0.1% cyclosporin (1 mg/mL) for the treatment of severe vernal keratoconjunctivitis: an evidence-based review and place in therapy. Clin Ophthalmol 13:1147–55
doi: 10.2147/OPTH.S181811
Leonardi A, Doan S, Amrane M, Ismail D, Montero J, Németh J et al (2019) A randomized, controlled trial of cyclosporine a cationic emulsion in pediatric vernal keratoconjunctivitis. Ophthalmology 126(5):671–681
doi: 10.1016/j.ophtha.2018.12.027
Fukushima A, Ohashi Y, Ebihara N, Uchio E, Okamoto S, Kumagai N et al (2014) Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. Br J Ophthalmol 98(8):1023–7
doi: 10.1136/bjophthalmol-2013-304453
Saboo US, Jain M, Reddy JC, Sangwan VS (2013) Demographic and clinical profile of vernal keratoconjunctivitis at a tertiary eye care center in India. Indian J Ophthalmol 61(9):486–489
doi: 10.4103/0301-4738.119431
Gokhale NS (2016) Systematic approach to managing vernal keratoconjunctivitis in clinical practice: severity grading system and a treatment algorithm. Indian J Ophthalmol 64(2):145
doi: 10.4103/0301-4738.179727
Zicari AM, Capata G, Nebbioso M, De Castro G, Midulla F, Leonardi L et al (2019) Vernal keratoconjunctivitis: an update focused on clinical grading system. Ital J Pediatr BioMed Central Ltd. https://doi.org/10.1186/s13052-019-0656-4
doi: 10.1186/s13052-019-0656-4
Chatterjee S, Agrawal D (2016) Tacrolimus in corticosteroid-refractory vernal keratoconjunctivitis. Cornea 35(11):1444–1448
doi: 10.1097/ICO.0000000000000918
McVeigh KA, Vakros G (2015) The eye drop chart: a pilot study for improving administration of and compliance with topical treatments in glaucoma patients. Clin Ophthalmol 5(9):813–819
Sacchetti M, Lambiase A, Mantelli F, Deligianni V, Leonardi A, Bonini S (2010) Tailored approach to the treatment of vernal keratoconjunctivitis. Ophthalmology 117(7):1294–9
doi: 10.1016/j.ophtha.2009.11.043
Suárez AL, Feramisco JD, Koo J, Steinhoff M (2012) Psychoneuroimmunology of psychological stress and atopic dermatitis: pathophysiologic and therapeutic updates. Acta Dermato-Venereologica 92(1):7–15
doi: 10.2340/00015555-1188
Castellsague J, Kuiper JG, Pottegård A, Berglind IA, Dedman D, Gutierrez L et al (2018) A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European longitudinal lymphoma and skin cancer evaluation – JOELLE study). Clin Epidemiol 13(10):299–310
doi: 10.2147/CLEP.S146442
Legendre L, Barnetche T, Mazereeuw-Hautier J, Meyer N, Murrell D, Paul C (2015) Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: a systematic review and meta-analysis. J Am Acad Dermatol 72(6):992–1002
doi: 10.1016/j.jaad.2015.02.1116
Cury Martins J, Martins C, Aoki V, Gois AFT, Ishii HA, da Silva EMK (2015) Topical tacrolimus for atopic dermatitis. Vol. 2015, Cochrane Database of Systematic Reviews. Wiley
Tennis P, Gelfand JM, Rothman KJ (2011) Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol 165(3):465–73
doi: 10.1111/j.1365-2133.2011.10363.x
Hui RL, Lide W, Chan J, Schottinger J, Yoshinaga M, Millares M (2009) Association between exposure to topical tacrolimus or pimecrolimus and cancers. Ann Pharmacother 43:1956–1963
doi: 10.1345/aph.1M278
Siegfried EC, Jaworski JC, Hebert AA (2013) Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol 14(3):163–78
doi: 10.1007/s40257-013-0020-1
Al-Amri AM (2014) Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis. Am J Ophthalmol 157(2):280–286
doi: 10.1016/j.ajo.2013.10.006
Dinning WJ (1976) Steroids and the eye-indications and complications. Postgrad Med J 52:634–638
doi: 10.1136/pgmj.52.612.634